Expert Says “The Starbucks of Cannabis” Could Reignite the Pot Boom in 2020!
· BDS Analytics estimates sales will grow from $20 billion in 2020 to $45 billion by 2024.
· “Cannabis company stocks are skyrocketing” – New York Post, May 20, 2020
By Greg Miller
Dear Fellow Investor,
After a lackluster 2019, cannabis stocks have come roaring back to life in 2020.
Aurora Cannabis (ACB) shares shot up 210.7% in five days in mid-May on news of stronger-than-expected sales due to Covid-19.
Other examples of recent gainers include :
Yet the cannabis stock that has me and many other experienced cannabis investors most excited is Chemesis International (CADMF) – the one cannabis company that has a realistic shot at bringing quality cannabis products to the masses.
Chemesis (CADMF) is one of the largest cannabis operators in Puerto Rico is preparing to have the capacity to produce 30,000 pounds of high-quality cannabis per year.
Now headed by vending executive Josh Rosenberg, an 18-year veteran of the Coca-Cola Company, Chemesis International (CADMF) is aiming to do for the cannabis market what Starbucks did for coffee, Coke did for soft drinks and Redbox did for DVDs.
These signature American companies are all about branding and mass distribution – taking simple products (coffee, soft drinks and DVDs) and making sure they can be easily purchased in every convenience store, fast food restaurant and gas station in America.
And that’s what Josh Rosenberg is doing with Chemesis International (CADMF)!
He’s setting out to create the number one cannabis brand in America – one state and territory at a time — and making sure its products are available virtually everywhere. Just as Starbucks perfected its branding in Seattle and then went on to capture 40% of the $47.5 billion U.S. coffee shop market, so, too, Chemesis (CADMF) wants to refine its cannabis branding in Puerto Rico and then capture a huge chunk of North America’s rapidly expanding cannabis market.
According to new projections by the market research firm BDS Analytics, sales of all cannabis products will likely DOUBLE just in the U.S. in the next four years alone, from $20 billion in 2020 to $45 billion by 2024.
And Chemesis (CADMF) plans on being the first moving in a nationally recognized brand – just like Starbucks is for coffee!
There are dozens of undervalued cannabis stocks out there right now, yet I believe that Chemesis (CADMF) is the best of the bunch for those seeking a high return.
Hello. My name is Greg Miller.
I’m a former Wall Street investment adviser and the co-founder of the National Institute for Cannabis Investors.
Since quitting Wall Street, I’ve made it my mission to bring institutional-quality investment research to the cannabis industry.
I’ve also been in the trenches as cannabis investing EXPLODED after 2017, helping ordinary people double their money on plays like Charlotte’s Web (CWBHF), Cresco Labs (CRLBF) and Innovative Industrial Properties (IIPR), to name just a few.
And here’s what you need to know: The U.S. cannabis market is making a comeback! Cannabis stocks took a beating in 2019, especially the large growers.For that reason, some investors wrongly assumed that demand for cannabis products has also declined.
Yet nothing could be further from the truth.
In reality, demand for cannabis has actually increased, especially since the Covid-19 crisis.
“The problem with the cannabis industry has never been the demand.”
“It’s been the lack of professionally managed companies that can give consumers what they want — when and where they want it.”
That’s why I believe cannabis investors should pay close attention to what Chemesis (CADMF) is doing.
It’s another one of those under-the-radar cannabis opportunities that could make you a serious amount of money.
Despite increasing demand for cannabis generally, supplies of retail products remain sharply limited.
One reason is lack of distribution.
Although cannabis is legal for recreational use in 14 states and for medical use in 33, there are relatively few retail establishments where cannabis products can be easily and legally purchased.
That’s why a company like Chemesis (CADMF) – which wants to put its branded, high-quality cannabis products in stores across America – could transform the entire cannabis industry!
By following the Starbucks model of distinctive branding and mass distribution, Chemesis (CADMF) could become “the” retail outlet for the purchase of cannabis products.
The potential is simply staggering.
By one estimate, there are still only 2,000 fully licensed cannabis dispensaries in the entire United States.
High Times Magazine estimates that in some states where cannabis is legal, such as Massachusetts, there are only 19 legal venues.
By comparison, there are currently…
… 27,000 Subway locations in the U.S….
… 13,172 Starbucks…
… 14,400 McDonalds…
… 11,366 Dunkin Donuts… and
… 7,800 7-11 stores.
That’s why I believe Chemesis (CADMF) could be a game-changing company for the cannabis industry!
It’s in the process of perfecting hugely-profitable cannabis retail outlets with the same high-quality and brand-recognition as Starbucks – like its Natural Ventures stores in Puerto Rico.
Once it finalizes its prototype in Puerto Rico, Chemesis (CADMF) plans to open additional dispensaries in states where it currently holds licenses, such as California.
And then, all bets are off!
Investing in Chemesis (CADMF) could be like investing in Starbucks in the early 1990s.
The similarity to Starbucks is not an exaggeration.
Back in the 1992, Starbucks went public with its initial public offering (IPO) at $17 per share.
Adjusted for stock splits and dividend income, that is the equivalent of just $0.28 per share today.
Early investors who took a $5,000 flyer on Starbucks saw their money grow into $1.4 million today.
And as a mid-tier cannabis retailer, Chemesis (CADMF) shares are in the “sweet spot” of between $0.50 and $2.00 per share .
At this price, investors can buy 1,000… 5,000… even 10,000 shares at a time – with life-changing potential profits.
And what is true of cannabis retail outlets is also true of cannabis products.
The truth is, there are few national companies producing the cannabis edibles, beverages and topical creams that consumers crave!
Despite the staggering potential profits, the regulatory headaches for consumable products are immense.
This, too, has created a HUGE opportunity for a well-managed “seed to sale” company like Chemesis (CADMF)!
Like Starbucks, Chemesis (CADMF) controls its entire supply chain. For Chemesis (CADMF), this means growing its own plants and extracting the healing oil to manufacturing edibles and distributing them in its own licensed stores.
For example, Chemesis (CADMF)’s line of Green Spirit edibles, produced by its subsidiary Natural Ventures, are found at most major cannabis retailers in Puerto Rico.
Plus, the company has recently signed $6 million in purchase agreements to supply dispensaries in Puerto Rico with its various cannabis products.
Just as Starbucks maintains strict quality control over its coffee bean suppliers, so, too, Chemesis (CADMF) has been able to produce the highest quality products at the lowest prices by acquiring and maintaining its own grow operations and manufacturing its own products.
It has 7,000 acres in total outdoor grow capacity, three manufacturing and cannabis oil extraction facilities, two large-scale packing and distribution centers, and ten active retail locations with three prequalified dispensaries.
And through its wholly owned subsidiary, Natural Ventures PR LLC, Chemesis (CADMF) markets an impressive catalogue of both THC and CDB products through a chain of licensed retail stores.
Chemesis’s ownership of all aspects of its business – what management gurus call “vertical integration” – thus gives it a huge advantage over other mid-tier cannabis companies seeking to dominate the national cannabis market.
Chemesis (CADMF) distributes and sells both of the two basic types of cannabis products:
For years, investors assumed that the primary market for cannabis lay in the THC side of the business.
Yet a new report from BDS Analytics and Arcview Market Research reveals that sales of CBD products alone will exceed $20 billion in the United States by 2024.
“We’re witnessing CBD maturing from a cannabis sub-category into a full-blown industry of its own,” said Roy Bingham, Co-Founder and CEO of BDS Analytics. “Our growth forecast for the CBD market, across all distribution channels, predicts a compound annual growth rate of 49 percent by 2024.”
Once again, Chemesis (CADMF) aims to be at the forefront of the rapidly expanding CBD market as regulatory changes will make CBD products available on the shelves of general retailers across the nation.
“The public wants high-quality cannabis products, both THC and CBD, and they want them in easy-to-access locations for a fair price,” Rosenberg said. “A company that can provide that will be able to write its own ticket.”
As a first step, Chemesis (CADMF) is already an early pioneer in bringing its top-quality, branded CBD products to the exploding “unattended retail” industry, itself estimated to be worth $25 billion in the U.S. alone.
The company is currently testing a state-of-the-art, age-verifying, self-service CBD vending kiosk in Terminal B of the Atlanta Airport.
And if all goes well, beginning in 2021, the company plans to install 10-15 CBD kiosks per month throughout commercial airports in the United States.
Convenience store locations, gyms and yoga studios would soon follow.
And make no mistake: A company that can put high-quality CBD products in easily accessible locations all across the United States should be on any investor’s radar.
For example, there are currently more than 41,000 Redbox kiosks operational in the United States.
That’s another reason why Chemesis (CADMF) could turn out to be one of the biggest cannabis-related plays of 2020…
To top it off, Chemesis CEO Josh Rosenberg may be the only man in America with the training and hands-on experience to create a “Starbucks” (national retail brand) and “Redbox” (CBD vending) model for the cannabis industry.
After 18 years at Coca-Cola that led to his heading up Coke’s “alternate route to market” distribution network, in 2013 Rosenberg took over as CEO of Accent Food Services, a leading vending and unattended retail company.
Rosenberg was brought in to take a small, regional company and, with strategic acquisitions and the revamping its distribution network, grew its sales 400%.
And just when the cannabis market is seeing record sales, Rosenberg is determined to do with cannabis what he did with nutritional products.
“Cannabis consumers want the same kind of high-quality, standardized products that companies like Starbucks and The Coffee Bean brought to the coffee industry,” Rosenberg explained.
This is huge. When it comes to cannabis, consumers want and expect a consistent experience every time – and this is what Chemesis (CADMF), with its standardized high-quality products, aims to provide.
That’s why I see Chemesis (CADMF) as a ground-floor opportunity like Starbucks.
Right now, Chemesis (CADMF) is like a stealth fighter flying below Wall Street’s radar screen, ready to jet upwards.
Yet once Wall Street gets wind of mergers between this company and the other major players in the cannabis market, the stock could take off like a proverbial rocket.
Chemesis (CADMF) has already completed a number of recent acquisitions that could multiply its gross sales many fold.
In fact, Chemesis (CADMF) is going to spin off one of those acquisitions into its own independent company. It has development licenses for CBD in one of the world’s lowest-cost growing regions, Colombia. If you own Chemesis (CADMF) shares before this transaction takes place, you’ll get “free” shares in a company operating in the future of medical cannabis – Latin America!
According to the market research firm Prohibition Partners, the legal Latin American cannabis industry is on track to grow from $125 million in 2020 to a staggering $12.7 billion by 2028 – an increase of 10,060%.
At the moment, the Chemesis (CADMF) is trading below $1 per share – but that likely won’t be for long.
Once word gets out about its plan to mass market cannabis products to the general public – to do for quality cannabis products what Starbucks did for coffee – I expect the big money will move in.
That’s why the time to buy Chemesis (CADMF) is NOW… before Wall Street finds out about it.
No guarantees, but I believe Chemesis (CADMF) could well turn out to be the next big cannabis blockbuster – the way Cronos Group (CRON) went from 90-cents a share in October 2016 to $21 in 2019, turning every $5,000 invested into $116,666.
Pot Stocks Are Skyrocketing Again Post-Covid. And as more people discover it, Chemesis (CADMF) is sure to as well.
Regulated Supply and Suppliers. There are few cannabis companies that are publicly traded, most are bloated, over-capitalized companies and failing miserably due to mismanagement. This creates an enormous opportunity for a “seed to sale” cannabis company like Chemesis (CADMF) with strong leadership and a clear focus to dominate.
Name Brand Products. Through its wholly owned subsidiary, Natural Ventures, Chemesis (CADMF) produces and distributes a complete catalogue of both THC and CBD products, including edibles, beverages, and topical creams.
It’s Already Dominating Its Market. Chemesis (CADMF) is already the one of the largest seed-to-consumer cannabis operator in Puerto Rico, bringing the standardization and quality control of a company like Starbucks to the cannabis market.
Corporate Quality Control. Chemesis (CADMF) is a fully-integrated, professionally run company that, like Starbucks, controls all aspects of its business, including growing its own raw material, manufacturing its own products, creating its own branding, and operating its own distribution channels. This will allow it to do for the cannabis what Starbucks did for brewed coffee and Redbox did for DVDs.
Headed by a Mass Distribution Expert. “Unattended retail” and vending machines are Chemesis (CADMF) CEO Josh Rosenberg’s specialty. He’s literally an award-winning expert in the industry. If anyone can bring CBD products to the masses, Rosenberg can!
A Starbucks-Like Opportunity. Chemesis (CADMF) shares currently sell for less than $0.00 – the same as Starbucks adjusted IPO price of $0.28 in 1992. Early investors in Starbucks made up to 275 times return on their investment. Could Chemesis be the next franchise blockbuster?
IMPORTANT NOTICE AND DISCLAIMER
THIS PUBLICATION IS AN ISSUER-PAID ADVERTISEMENT. This paid advertisement includes a stock profile of Chemesis International, Inc. (OTCQB: CADMF). To enhance public awareness of CADMF and its securities, the issuer has provided Promethean Marketing, Inc. (“Promethean”) with a total budget of approximately three hundred thousand dollars ($300,000) to cover the costs associated with this advertisement. In connection with this effort, Promethean has paid the author of this advertisement, Greg Miller, eight thousand five hundred dollars ($8,500) in cash out of the total budget. The website hosting this advertisement, All Marijuana Stocks, is owned by Summit Publishing Group, Inc. (“Summit”), an affiliate of Promethean. Neither Summit nor All Marijuana Stocks have been paid to host this advertisement. As a result of this advertisement, Greg Miller may also receive revenue from the sale of other products to readers and All Marijuana Stocks may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. Promethean will retain any excess sums after all expenses are paid. Promethean has previously managed budgets from the issuer of approximately $2,700,000 and $100,000 for advertising campaigns, which ended in July 2019 and September 2019, respectively. Greg Miller is solely responsible for the contents of this advertisement. To more fully understand the All Marijuana Stocks website or service, please review its full Disclaimer and Disclosure Policy located at https://allmarijuanastocks.com/legal-disclaimer/].
MAY HOLD SECURITIES DISCUSSED. As of the date the advertisement is posted to the All Marijuana Stocks website, none of Promethean, All Marijuana Stocks, Summit, or Greg Miller holds the securities of CADMF and none intends to purchase such securities for a period of ninety (90) days following the end of this advertising campaign. The owner of Promethean owns shares of CADMF through FSM Ventures, which shares were purchased from the issuer through a private placement. The owner of Promethean currently intends to sell some of that position.
NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. None of Promethean, All Marijuana Stocks, Summit, or Greg Miller, or any of their respective owners or employees is registered as a securities broker-dealer, broker, an investment advisor, or an investment advisor representative with the U.S. Securities and Exchange Commission (SEC), any state securities regulatory authority, or any self-regulatory organization.
SUBSTANTIAL RISK IN INVESTMENT. Any individual who chooses to invest in the securities of CADMF or any other securities including those mentioned in this advertisement should do so with caution. Investing or transacting in securities, and in particular micro-cap securities, involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers bear responsibility for their own investment research and decisions and should review all investment decisions with a licensed or registered investment professional.
USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. None of Promethean, All Marijuana Stocks, Summit, or Greg Miller undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by CADMF at https://www.sec.gov/edgar/searchedgar/companysearch.html.
 From $5.80 at the open on May 14, 2020 to $17.40 at the close on May 21, 2020. https://www.marketwatch.com/story/aurora-cannabis-stock-jumps-as-pot-sales-grow-faster-than-expected-2020-05-14
 From a closing price of $6.00 per share on March 18, 2020, to $15.29 at the close on July 15, 2020, per Barchart.com. According to my online percentage calculator, that is an increase of 154.8%. See https://percentagecalculator.net/
 From a closing price of $2.04 per share on March 18, 2020, to $5.43 at the close on July 15, 2020, a gain of 166.1%.
 From a closing price of $4.55 per share on March 18, 2020, to $11.50 at the close on July 15, 2020, a gain of 152.7%.
 From a closing price of $2.75 per share on March 18, 2020, to $7.28 at the close on July 15, 2020, a gain of 164.7%.
 From a closing price of $9.73 per share on March 18, 2020, to $18.15 at the close on July 15, 2020, a gain of 86.5%.
 From a closing price of $4.17 per share on March 18, 2020, to $7.08 at the close on July 15, 2020, a gain of 69.7%.
 $ 78.60 at the close on May 27, 2020.
 $77 per share divided by $0.28 per share = 275
 Actually, $1,374,999.
 Regulatory caution
 Get accurate numbers
 6 vends per day x $25 each = $150 x 30 = $4,500
 410 machines x $3,000 = $1,230,000
 04:41 of interview.